Relative risk analysis of safety profile of lanreotide autogel/depot vs. placebo in patients with pancreatic and intestinal neuroendocrine tumours

Konference: 2015 40th Congress ESMO a 18th ECCO - účast ČR

Kategorie: Gastrointestinální nádory

Téma: Postery

Číslo abstraktu: P332/2370

Autoři: Prof. M.D. Alexandria T. Phan; Prof. M.D. Martyn E. Caplin, FRCP; Prof. Dr. Marianne E. Pavel, M.D.; Prof. M.D. Jaroslaw B. Cwikla; M.D. Markus Raderer; MUDr. Eva Sedláčková, MBA; Prof. M.D. Guillaume Cadiot, Ph.D.; MD Edward M. Wolin; MD Jaume Capdevila; M.D. Lucy R. Wall ; M.D. Guido Rindi, Ph.D.; Alison Langley; Edda Gomez-Panzani; Prof. M.D. Philippe B. Ruszniewski

Background: In the CLARINET study (NCT00353496), progression-free survival (PFS) of patients with metastatic pancreatic and intestinal neuroendocrine tumours (NETs) was significantly increased with lanreotide Autogel (Depot in USA) 120mg vs placebo (hazard ratio [HR] for progressive disease [PD]/death 0.47 [95% confidence interval CI: 0.30, 0.73]). We now present detailed analysis of the safety and tolerability data from CLARINET evaluating the relative risk of adverse events.

Methods: Patients with metastatic grade 1/2 (Ki-67 <10%) non-functioning pancreatic and intestinal NETs received lanreotide Autogel 120mg (n=101) or placebo (n=103) for 96 weeks or until death/disease progression. The relative risks and 95%CIs of any adverse event occurring in ≥5% of patients in either group were calculated post hoc for lanreotide vs. placebo.

Results: The overall incidence of adverse events was similar for lanreotide- and placebo-treated patients (88% vs 90%). The most common adverse events were gastrointestinal disorders, which occurred in 67% of the lanreotide-treated group vs. 63% of the placebo-treated group (RR 1.1 [0.9, 1.3]). Of these, diarrhoea was the most common individual adverse event (35% vs 35%; RR 1.0 [0.7, 1.4]). None of the adverse events occurring in ≥5% of either group were statistically significantly different between the lanreotide and placebo treated patients when based on the RRs although the CIs for the RRs were wide in several cases (lower limit of CIs were ≤1). The most frequent adverse events in either group are shown in the Table.

Conclusions: No new safety signals for lanreotide were identified in the CLARINET study supporting its favourable benefit–risk profile in patients with pancreatic and intestinal NETs.

Table: RRs for most frequent AEs (occurring in ≥10% in either group)
Adverse event Lanreotide, n (%) (N=101) Placebo, n (%) (N=103) RR (95%CI)
Gastrointestinal      
 Diarrhea 35 (34.7) 36 (35.0) 1.0 (0.7, 1.4)
 Abdominal pain 24 (23.8) 17 (16.5) 1.4 (0.8, 2.5)
 Vomiting 19 (18.8) 9 (8.7) 2.2 (1.0, 4.5)
 Nausea 14 (13.9) 14 (13.6) 1.0 (0.5, 2.0)
 Constipation 12 (11.9) 13 (12.6) 0.9 (0.5, 2.0)
 Flatulence 12 (11.9) 9 (8.7) 1.4 (0.6, 3.1)
Musculoskeletal      
 Headache 16 (15.8) 11 (10.7) 1.5 (0.7, 3.0)
 Back pain 12 (11.9) 11 (10.7) 1.1 (0.5, 2.4)
Hepatobiliary      
 Cholelithiasis 14 (13.9) 7 (6.8) 2.0 (0.9, 4.8)
Vascular      
 Hypertension 13 (12.9) 5 (4.9) 2.7 (1.0, 7.2)
General and administration site      
 Fatigue 10 (9.9) 15 (14.6) 0.7 (0.3, 1.4)
Infections and infestations      
 Nasopharyngitis 9 (8.9) 16 (15.5) 0.6 (0.3, 1.2)

 

For significant difference between treatment groups, lower limit of CIs would need to be >1.

Conflict of interest: Ownership: Authors Langley and Gomez-Panzani are employees of Ipsen, France.

Keywords:
lanreotide
neuroendocrine tumour
safety
 

Datum přednesení příspěvku: 28. 9. 2015